---
title: "Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285271002.md"
description: "Aura Biosciences has completed a public offering of 39,591,000 common shares at $6.00 and pre-funded warrants for 3,800,000 shares at $5.99999, netting approximately $280.8 million. The offering, underwritten by Leerink Partners, TD Securities, and Evercore, closed on May 5, 2026. The company plans to allocate $241.8 million to advance clinical programs and general corporate purposes, while $39.0 million will be used to repurchase shares from Matrix at $5.64 each."
datetime: "2026-05-05T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285271002.md)
  - [en](https://longbridge.com/en/news/285271002.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285271002.md)
---

# Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore

Aura Biosciences entered into an underwriting agreement for a public offering of 39,591,000 common shares at $6.00 and pre-funded warrants for 3,800,000 shares at $5.99999. Underwriters exercised in full a 6,508,650-share option, and the offering closed on May 5, 2026, yielding approximately $280.8 million in net proceeds. The company plans to use $241.8 million to advance clinical programs, including bel-sar, and for general corporate purposes, and about $39.0 million to repurchase 6,922,870 shares from Matrix at $5.64 per share.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for public offering of common stock and pre-funded warrants
-   **Counterparty**: Leerink Partners, TD Securities (USA) and Evercore Group, as representatives of the underwriters
-   **Signed / Effective**: May 04 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Fund clinical programs and general corporate purposes

Original SEC Filing: Aura Biosciences, Inc. \[ AURA \] - 8-K - May. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AURA.US](https://longbridge.com/en/quote/AURA.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)

## Related News & Research

- [Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data](https://longbridge.com/en/news/286990060.md)
- [Matrix Capital Management Comp Sells 6,922,870 Shares of Aura Biosciences (NASDAQ:AURA) Stock](https://longbridge.com/en/news/286058101.md)
- [Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | AURA Stock News](https://longbridge.com/en/news/286966217.md)
- [Aura Biosciences Q1 net loss widens on higher R&D costs](https://longbridge.com/en/news/285988817.md)
- [2 AI Stocks That Will Still Be Dominant When Today's Hype Has Faded](https://longbridge.com/en/news/286951863.md)